Description

30TH ANNUAL SYMPOSIUM • 2026 EDITION

30th Annual Heart Failure 2026: An Update on Therapy

Heart Failure 2026: An Update on Therapy delivers a comprehensive, clinically focused review of contemporary heart-failure prevention, diagnosis, and management. The program covers guideline-directed medical therapy, acute decompensated heart failure, cardiogenic shock, cardiomyopathies, genetic testing, device therapy, pulmonary hypertension, LVADs, transplantation, artificial intelligence, and emerging cardiovascular treatments.

Videos

Conference Recordings

PDFs

Course Resources

VTT

Subtitle Files

2026

Latest Edition

❤️

Course Details

30th Annual Heart Failure 2026 — An Update on Therapy

Original Dates: March 13–14, 2026 • Hybrid Symposium • Millennium Biltmore Hotel and Online

About Heart Failure 2026

30th Annual Heart Failure 2026: An Update on Therapy continues a three-decade tradition of delivering clinically relevant updates on the prevention, diagnosis, and management of acute and chronic heart failure.

The curriculum combines expert lectures, case discussions, treatment updates, and interactive faculty sessions designed to help cardiovascular clinicians manage heart failure across a broad range of etiologies and clinical settings.

Major areas include guideline-directed medical therapy, HFrEF, HFpEF, acute decompensated heart failure, congestion, cardiogenic shock, chronic kidney disease, atrial fibrillation, hypertrophic cardiomyopathy, myocarditis, amyloidosis, pulmonary hypertension, genetic testing, device therapy, LVADs, transplantation, and artificial intelligence.

Why Choose Heart Failure 2026

✓ Comprehensive heart-failure update covering both acute and chronic disease
✓ Practical GDMT guidance for HFrEF, HFpEF, congestion, and cardiorenal disease
✓ Advanced management strategies for cardiogenic shock, LVADs, and transplantation
✓ Complex cardiomyopathy coverage including HCM, myocarditis, amyloidosis, and peripartum cardiomyopathy
✓ Emerging therapies including gene therapy, stem-cell therapy, bio-omics, and AI
✓ Expert-led case discussions focused on real-world clinical decision-making
✓ Two full days of education organized across six scientific sessions

Clinical Areas Covered

Heart-Failure Pharmacotherapy: GDMT • Finerenone • Vericiguat • Digitoxin • Diuretics • Hyperkalemia Management • TTR Amyloidosis Therapy
Acute and Advanced Heart Failure: Acute Decompensated Heart Failure • Congestion • Cardiogenic Shock • Hemodynamic Classification • LVAD • Heart Transplantation
Cardiomyopathies: Hypertrophic Cardiomyopathy • Ischemic Cardiomyopathy • Peripartum Cardiomyopathy • Methamphetamine-Associated Cardiomyopathy • Myocarditis
Precision and Emerging Medicine: Genetic Testing • Gene Therapy • Stem-Cell Therapy • Bio-Omics • Artificial Intelligence
Associated Conditions: Chronic Kidney Disease • Atrial Fibrillation • Obesity • Pulmonary Hypertension • Amyloidosis • Fabry Disease • Recurrent Pericarditis

Learning Objectives

🎯 Upon Completion, Participants Should Be Able To

✓ Review contemporary guidelines and therapeutic options for hypertension, hyperlipidemia, HFrEF, and HFpEF.

✓ Apply advanced strategies for acute decompensated heart failure and cardiogenic shock.

✓ Optimize treatment for patients with heart failure and chronic kidney disease.

✓ Review management of atrial fibrillation in patients with heart failure.

✓ Evaluate treatment options for hypertrophic cardiomyopathy, myocarditis, amyloidosis, and other myocardial diseases.

✓ Discuss contemporary approaches to obesity and pulmonary hypertension in heart-failure patients.

✓ Understand emerging applications of genetic testing, gene therapy, stem-cell therapy, device therapy, and AI.

Symposium Leadership and Faculty

Symposium Leader: Uri Elkayam, MD, FACC

The faculty includes recognized experts in heart failure, cardiomyopathy, interventional cardiology, cardiovascular pharmacotherapy, genetics, pulmonary hypertension, mechanical circulatory support, and transplantation.

Uri Elkayam, MD, FACC • Barry Greenberg, MD • Clyde Yancy, MD • Gregg Fonarow, MD • Ileana L. Piña, MD • Akshay Desai, MD • William Abraham, MD • Marvin Konstam, MD • Eric Yang, MD • Leslie Cooper, MD • Nir Uriel, MD • Mazen Hanna, MD • Josh Hare, MD • Thomas Heywood, MD • Jessica Wang, MD

Complete Scientific Curriculum

❤️ Friday, March 13 — Session I

Introduction to the 30th Annual Symposium — Uri Elkayam, MD, FACC

Management of Hospitalized Patients with Decompensated Heart Failure — Uri Elkayam, MD, FACC

Balancing GDMT and Hyperkalemia — Ileana L. Piña, MD

Digitoxin in Heart Failure: A Comeback for Digitalis? — Tien Ng, PharmD

Finerenone for Heart Failure and Chronic Kidney Disease — Akshay Desai, MD

Vericiguat in Heart Failure: When and How to Use It — Barry Greenberg, MD

Contemporary Management of HFpEF — Akshay Desai, MD

💊 Friday, March 13 — Session II

Our Journey with Diuretics: 240 Years, and How Far Have We Come? — Marvin Konstam, MD

Treating Congestion in Acute Decompensated Heart Failure — William Abraham, MD

Cancer Immunotherapy, Myocarditis, and Cardiovascular Implications — Eric Yang, MD

Myosin Inhibitors in Obstructive and Non-Obstructive HCM — Jessica Wang, MD

Contemporary Management of Obesity in Heart Failure — Norman Lepor, MD

🫀 Saturday, March 14 — Session III

GDMT for Chronic HFrEF: How to Maximize the Benefits — Gregg Fonarow, MD

Cardiogenic Shock: Hemodynamic Classification and Management — Rola Khedraki, MD

Percutaneous Coronary Intervention in Ischemic Cardiomyopathy — Christina Economides, MD

Bio-Omics in Heart-Failure Diagnosis and Therapy — Kirkwood Adams, MD

🧬 Saturday, March 14 — Session IV

Genetic Testing for Cardiomyopathy — Josh Hare, MD

Gene Therapy for Patients with Cardiomyopathy — Barry Greenberg, MD

Stem-Cell Therapy for Myocardial Disease — Josh Hare, MD

Methamphetamine-Associated Cardiomyopathy — Uri Elkayam, MD

Atrial Fibrillation in Patients with Heart Failure — Anil Bhandari, MD

🎤 Saturday, March 14 — Session V

Keynote: 30 Years of Innovation in Heart-Failure Management — Clyde Yancy, MD

Bromocriptine in Peripartum Cardiomyopathy — Uri Elkayam, MD

What Is New in Myocarditis: ESC 2025 Guideline Update — Leslie Cooper, MD

Pulmonary Hypertension: New Drugs and How to Use Them — Thomas Heywood, MD

Innovations in Device Therapy for Heart Failure — William Abraham, MD

🤖 Saturday, March 14 — Session VI

Artificial Intelligence in Heart-Failure Management — Nir Uriel, MD

Autonomic Modulation in Heart-Failure Treatment — Marvin Konstam, MD

LVAD versus Heart Transplantation — Nir Uriel, MD

Drug-Therapy Selection in Transthyretin Amyloidosis — Mazen Hanna, MD

Additional Program Content: case discussions and industry-supported, non-CME product-theatre sessions covering recurrent pericarditis, Fabry disease, and symptomatic obstructive hypertrophic cardiomyopathy.

Who Should Take Heart Failure 2026

This program is designed for clinicians involved in the prevention, diagnosis, and management of heart failure.

✓ Cardiologists ✓ Advanced Heart-Failure Specialists ✓ Internists
✓ Primary Care Physicians ✓ Intensivists ✓ Hospital-Based Clinicians
✓ Pharmacists ✓ Nurses ✓ Advanced-Practice Providers
✓ Cardiovascular Fellows and Other Healthcare Professionals

Course Package

🎥 Video Recordings

Continuous conference recordings covering the individual lectures and scientific sessions listed above.

💬 VTT Subtitle Files

Subtitle files are included with the course package where available.

📄 PDF Resources

Supporting PDF resources and educational materials included in the available course files.

📦 Package Information

Video count: [ADD COUNT]
VTT count: [ADD COUNT]
PDF count: [ADD COUNT]
Total size: [ADD SIZE] GB

Important: Replace the package placeholders with the verified numbers of videos, VTT subtitle files, PDF resources, and the total file size before publishing this product.

Reviews

There are no reviews yet.

Be the first to review “Complete Conference Management 30th Annual Heart Failure 2026”

You must be logged in to post a review.

Complete Conference Management 30th Annual Heart Failure 2026